Pathology of Prostatic Stromal Tumors of Uncertain Malignant Potential 

No Results

No Results

processing….

Stromal tumors arising from the specialized stroma of the prostate are uncommon proliferations with several histologic patterns. The term stromal tumors of uncertain malignant potential (STUMP) was coined to describe a proliferation of stromal cells that is behaviorally and histologically distinct from benign hyperplasia and whose behavior cannot be predicted by its histologic appearance (see the images below). ^{[1, 2, 3]}

The neoplastic nature of these proliferations remains controversial, with arguments favoring these lesions to be hyperplastic or pseudosarcomatous processes existing to date. ^{[4, 5, 6, 7]} On the opposite spectrum of malignancy, true stromal sarcomas represent the malignant counterpart of lesions arising in the specialized stroma and are not discussed in this article.

Although the phyllodes pattern of proliferation has been included with STUMP by some authors, phyllodes tumors of the prostate will not be discussed in this article because of certain histologic differences. ^[8] The occasional coexistence of STUMP with stromal sarcomas (or progression from STUMP to sarcomas) and the few reported cases that have shown recurrence make the term STUMP acceptable. ^{[1, 9, 10, 8, 11]}

Stromal tumors of uncertain malignant potential (STUMP) are rare. ^{[8, 9, 10, 12, 13, 14, 15]} Because STUMP is a newly described entity, reports using other nomenclature likely refer to the same lesion, including terms such as atypical spindle cell proliferations, prostatic stromal hyperplasia with bizarre nuclei, bizarre leiomyoma, atypical stromal hyperplasia, and stromal hyperplasia with atypia. ^{[4, 16, 6, 7]}

The etiology and the pathogenesis of stromal tumors of uncertain malignant potential (STUMP) are unknown. No risk factors have been associated with these proliferations.

Stromal tumors of uncertain malignant potential (STUMP) arise in the specialized stroma of the prostate and do not seem to display any zonal predilection. Both transitional zones and peripheral zones of the prostate have been reported to contain these lesions, predominantly the latter. ^[10] A case of an extraprostatic STUMP has been reported. ^[15] A heterogeneous midline mass extending from the prostate base is sometimes seen by ultrasound examination. ^[17]

Stromal tumors of uncertain malignant potential (STUMP) have been reported in both young patients and elderly patients (age range, 27-83 y), with most patients older than 50 years.

Patients present most often with urinary and/or fecal obstruction, hematuria, abnormal rectal examination with a rectally palpable mass, or elevated prostate specific antigen (PSA) levels. Association with adenocarcinoma of the prostate has been reported in a small percentage of cases. ^{[1, 8, 10]}

Stromal tumors of uncertain malignant potential (STUMP) are grossly characterized by solid masses with occasional cystic spaces filled with mucinous or clear fluid.

Stromal tumors of uncertain malignant potential (STUMP) are stromal proliferations characterized by hypercellularity and/or cytologic atypia without evidence of true sarcomatous transformation. The atypical stromal cells have enlarged nuclei with nuclear hyperchromasia and occasional multinucleation. Few or no mitotic figures are present in reported cases of STUMP, and the occurrence of atypical mitoses should make the pathologist highly suspicious of a prostatic stromal sarcoma or other sarcomas involving the prostate. An association with prostatic glands is common, which are histologically benign.

Four different patterns of STUMP have been described, as follows:

Degenerative atypia with hypercellularity

Degenerative atypia without hypercellularity

Phyllodes tumor

Myxoid pattern, which is set apart by extensive overgrowth of myxoid stroma that resembles the stroma of benign prostatic hyperplasia.

STUMPs may have a mixture of patterns.

Histologic pattern recognition is helpful in the identification of these lesions, but there is no association of histologic pattern with aggressive local growth or progression to sarcoma. Although the seminal paper on the categorization of STUMP argued that a subset of these lesions may reflect hyperplastic processes, criteria allowing separation of some atypical hyperplastic lesions from STUMP have not been established. ^[1]

Nagar and Epstein systematically described the epithelial proliferations occurring in STUMP and suggested from their findings that, within STUMPs, there is epithelial-mesenchymal crosstalk, as has been described in benign prostate and prostatic carcinogenesis. According to the authors, in unusual cases of STUMP, the epithelial proliferation may predominate to the extent that it can mask the diagnosis of STUMP. ^[18]

In the Nagar and Epstein study, the most common abnormalities were glandular crowding in 35 of 70 cases (50%), a very prominent basal cell layer in some glands in 32 of 70 cases (46%), and prominent papillary infolding in 13 of 70 cases (19%). Other epithelial changes within the STUMP included cystically dilated glands; basal cell hyperplasia; urothelial metaplasia; squamous metaplasia; cribriform hyperplasia; adenosis; and high-grade PIN, low-grade PIN, and partial atrophy. The glandular component of STUMP was histologically normal in 12 (17%) cases. ^[18]

Immunohistochemical staining of stromal tumors of uncertain malignant potential (STUMP) reveals positivity with vimentin, progesterone receptor, actin, and CD34 in variable amounts. ^[19] A few cases also show estrogen receptor positivity. Beta-catenin was reportedly positive in one case of STUMP.

Ki-67 proliferative index is low but not discriminatory from stromal sarcomas. Negativity for CD117 allows distinction from gastrointestinal stromal tumors in small biopsy samples.

No information is available on genetic alterations of stromal tumors of uncertain malignant potential (STUMP).

A study by Pan et al was conducted to detect the chromosomal imbalances in stromal sarcoma and STUMP by using array comparative genomic hybridization (aCGH). The study found that stromal sarcoma and STUMP shared similar profiles of chromosomal imbalances (mainly deletions of chromosomes 13, 14, and 10). ^[20]

Stromal tumors of uncertain malignant potential (STUMP) are most often confined to the prostate.

Patients with stromal tumors of uncertain malignant potential (STUMP) have a good prognosis, and most cases of STUMP do not seem to behave aggressively. In fact, it has been argued that they represent benign stromal hyperplasia with reactive atypia similar to stromal changes seen in other sites, such as the cervix, vagina, vulva, bladder, and breast. ^{[21, 7]} However, Herawi et al reported that 16% (7/43) of STUMPs progressed to or were subsequently found to be associated with prostatic stromal sarcomas. ^[10]

Gaudin PB, Rosai J, Epstein JI. Sarcomas and related proliferative lesions of specialized prostatic stroma: a clinicopathologic study of 22 cases. Am J Surg Pathol. 1998 Feb. 22(2):148-62. [Medline].

Michaud S, Moreau A, Braud G, et al. [Prostatic Stromal Tumors of Uncertain Malignant Potential (STUMP): definition, pathology, prognosis and management]. Prog Urol. 2012 Oct. 22(12):688-91. [Medline].

Murer LM, Talmon GA. Stromal tumor of uncertain malignant potential of the prostate. Arch Pathol Lab Med. 2014 Nov. 138(11):1542-5. [Medline].

Attah EB, Nkposong EO. Phyllodes type of atypical prostatic hyperplasia. J Urol. 1976 Jun. 115(6):762-4. [Medline].

Young RH, Scully RE. Pseudosarcomatous lesions of the urinary bladder, prostate gland, and urethra. A report of three cases and review of the literature. Arch Pathol Lab Med. 1987 Apr. 111(4):354-8. [Medline].

Tetu B, Ro JY, Ayala AG, Srigley JR, Begin LR, Bostwick DG. Atypical spindle cell lesions of the prostate. Semin Diagn Pathol. 1988 Aug. 5(3):284-93. [Medline].

Hossain D, Meiers I, Qian J, MacLennan GT, Bostwick DG. Prostatic stromal hyperplasia with atypia: follow-up study of 18 cases. Arch Pathol Lab Med. 2008 Nov. 132(11):1729-33. [Medline].

Hansel DE, Herawi M, Montgomery E, Epstein JI. Spindle cell lesions of the adult prostate. Mod Pathol. 2007 Jan. 20(1):148-58. [Medline].

Wee HM, Ho SH, Tan PH. Recurrent prostatic stromal tumour of uncertain malignant potential (STUMP) presenting with urinary retention 6 years after transurethral resection of prostate (TURP). Ann Acad Med Singapore. 2005 Aug. 34(7):441-2. [Medline].

Herawi M, Epstein JI. Specialized stromal tumors of the prostate: a clinicopathologic study of 50 cases. Am J Surg Pathol. 2006 Jun. 30(6):694-704. [Medline].

Kawamura N, Nakai Y, Minato N, et al. [Case report of prostatic stromal tumor of uncertain malignant potential (STUMP)]. Hinyokika Kiyo. 2010 Apr. 56(4):237-40. [Medline].

Kakuta Y, Kobayashi Y, Tanaka M, Yazawa K, Harada Y, Itoh K. [A case of prostatic stromal tumor of uncertain malignant potential]. Hinyokika Kiyo. 2005 Dec. 51(12):843-6; discussion 846-7. [Medline].

Kawamorita N, Inaba Y, Soma F, Katayama Y, Mikami Y. [Giant phyllodes tumor of the prostate]. Nippon Hinyokika Gakkai Zasshi. 2007 Sep. 98(6):781-5. [Medline].

Fukuhara S, Matsuoka Y, Hanafusa T, et al. [A case report of prostatic stromal tumor of uncertain malignant potential (STUMP)]. Hinyokika Kiyo. 2008 May. 54(5):377-81. [Medline].

Roos FC, Sommer S, Hampel C, Melchior SW, Thuroff JW. Extraprostatic spindle cell stromal tumor of the prostate: case report. Urology. 2008 Jun. 71(6):1226.e13-5. [Medline].

Persaud V, Douglas LL. Bizarre (atypical) leiomyoma of the prostate gland. West Indian Med J. 1982 Dec. 31(4):217-20. [Medline].

Petersen RO, Sesterhenn IA, Davis CJ. Prostate. Urologic Pathology. 3rd ed. Philadelphia: Lippincott, Williams & Wilkins; 2008. 451-560.

Nagar M, Epstein JI. Epithelial proliferations in prostatic stromal tumors of uncertain malignant potential (STUMP). Am J Surg Pathol. 2011 Jun. 35(6):898-903. [Medline].

De Berardinis E, Busetto GM, Antonini G, et al. Incidental prostatic stromal tumor of uncertain malignant potential (STUMP): histopathological and immunohistochemical findings. Urologia. 2012. 79(1):65-8. [Medline].

Pan CC, Epstein JI. Common chromosomal aberrations detected by array comparative genomic hybridization in specialized stromal tumors of the prostate. Mod Pathol. 2013 Nov. 26(11):1536-43. [Medline].

Pitt MA, Roberts IS, Agbamu DA, Eyden BP. The nature of atypical multinucleated stromal cells: a study of 37 cases from different sites. Histopathology. 1993 Aug. 23(2):137-45. [Medline].

Fabio R Tavora, MD, PhD Associate Medical Director, Argos Laboratory, Visiting Scientist, Paulista Medical School, Universidade Federal de São Paulo (EPM/UNIFESP), Brazil

Fabio R Tavora, MD, PhD is a member of the following medical societies: College of American Pathologists, United States and Canadian Academy of Pathology, International Society of Urological Pathology

Disclosure: Nothing to disclose.

Liang Cheng, MD Professor of Pathology and Urology, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine; Chief, Genitourinary Pathology Service, Indiana University Health

Liang Cheng, MD is a member of the following medical societies: American Association for Cancer Research, American Urological Association, College of American Pathologists, United States and Canadian Academy of Pathology, International Society of Urological Pathology, Arthur Purdy Stout Society

Disclosure: Nothing to disclose.

Pathology of Prostatic Stromal Tumors of Uncertain Malignant Potential 

Research & References of Pathology of Prostatic Stromal Tumors of Uncertain Malignant Potential |A&C Accounting And Tax Services
Source

Share on Facebook

Tweet

Follow us